JP2018503092A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018503092A5 JP2018503092A5 JP2017536828A JP2017536828A JP2018503092A5 JP 2018503092 A5 JP2018503092 A5 JP 2018503092A5 JP 2017536828 A JP2017536828 A JP 2017536828A JP 2017536828 A JP2017536828 A JP 2017536828A JP 2018503092 A5 JP2018503092 A5 JP 2018503092A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- cancer
- priming
- profile
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562102499P | 2015-01-12 | 2015-01-12 | |
| US62/102,499 | 2015-01-12 | ||
| PCT/US2016/013003 WO2016115105A1 (en) | 2015-01-12 | 2016-01-12 | Context dependent diagnostics test for guiding cancer treatment |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018503092A JP2018503092A (ja) | 2018-02-01 |
| JP2018503092A5 true JP2018503092A5 (https=) | 2019-01-24 |
| JP6774951B2 JP6774951B2 (ja) | 2020-11-04 |
Family
ID=56406281
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017536828A Expired - Fee Related JP6774951B2 (ja) | 2015-01-12 | 2016-01-12 | 癌処置をガイドするためのコンテクストに依存する診断試験 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10793915B2 (https=) |
| EP (1) | EP3245301B1 (https=) |
| JP (1) | JP6774951B2 (https=) |
| KR (1) | KR20170126867A (https=) |
| CN (1) | CN107406881B (https=) |
| AU (1) | AU2016206882B2 (https=) |
| CA (1) | CA2974240A1 (https=) |
| HK (1) | HK1247250A1 (https=) |
| WO (1) | WO2016115105A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9901574B2 (en) | 2015-04-20 | 2018-02-27 | Tolero Pharmaceuticals, Inc. | Predicting response to alvocidib by mitochondrial profiling |
| ES2739749T3 (es) | 2015-05-18 | 2020-02-03 | Tolero Pharmaceuticals Inc | Profármacos de alvocidib que tienen biodisponibilidad aumentada |
| MX2018001289A (es) | 2015-08-03 | 2018-04-30 | Tolero Pharmaceuticals Inc | Terapias de combinacion para el tratamiento del cancer. |
| WO2018094275A1 (en) | 2016-11-18 | 2018-05-24 | Tolero Pharmaceuticals, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
| KR20190099260A (ko) | 2016-12-19 | 2019-08-26 | 톨레로 파마수티컬스, 인크. | 프로파일링 펩티드 및 감도 프로파일링을 위한 방법 |
| EP3385715A1 (en) | 2017-04-04 | 2018-10-10 | Medizinische Hochschule Hannover | Analytical process for predicting the therapeutic effect of bh3 mimetics |
| WO2019055579A1 (en) | 2017-09-12 | 2019-03-21 | Tolero Pharmaceuticals, Inc. | TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR |
| CN108070562A (zh) * | 2018-02-03 | 2018-05-25 | 金华市中心医院 | 一种“双打击”弥漫大b细胞淋巴瘤细胞系制备方法 |
| PT110722B (pt) * | 2018-05-03 | 2021-08-17 | Instituto De Patologia E Imunologia Molecular Da Univ Do Porto Ipatimup | Uso de anticorpos para o antigénio thomsen-friedenreich num método e estojo para avaliação de instabilidade de microsatelites |
| US11034710B2 (en) | 2018-12-04 | 2021-06-15 | Sumitomo Dainippon Pharma Oncology, Inc. | CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer |
| US11793802B2 (en) | 2019-03-20 | 2023-10-24 | Sumitomo Pharma Oncology, Inc. | Treatment of acute myeloid leukemia (AML) with venetoclax failure |
| US20230187075A1 (en) * | 2021-12-14 | 2023-06-15 | Shuhua Zheng | Method and system for artificial intelligence based risk stratification for glioma |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5622852A (en) | 1994-10-31 | 1997-04-22 | Washington University | Bcl-x/Bcl-2 associated cell death regulator |
| GB9422836D0 (en) * | 1994-11-11 | 1995-01-04 | Wainscoat James | Monitoring malignant disease |
| US5955593A (en) | 1996-09-09 | 1999-09-21 | Washington University | BH3 interacting domain death agonist |
| WO1998009643A1 (en) | 1996-09-09 | 1998-03-12 | Washington University | Modulation of apoptosis by serine phosphorylation of blc-xl/blc-2 associated cell death regulator |
| US5856445A (en) | 1996-10-18 | 1999-01-05 | Washington University | Serine substituted mutants of BCL-XL /BCL-2 associated cell death regulator |
| US5981201A (en) | 1997-01-08 | 1999-11-09 | Beth Israel Deaconess Medical Center | Methods of detection and treatment of breast cancer |
| GB9704444D0 (en) | 1997-03-04 | 1997-04-23 | Isis Innovation | Non-invasive prenatal diagnosis |
| WO1999014321A1 (en) | 1997-09-17 | 1999-03-25 | The Walter And Eliza Hall Institute Of Medical Research | Novel therapeutic molecules |
| AU9402898A (en) | 1997-09-26 | 1999-04-23 | Washington University | Cell death agonists |
| US6165732A (en) | 1997-10-14 | 2000-12-26 | Washington University | Method for identifying apoptosis modulating compounds |
| US7026456B1 (en) | 1998-01-23 | 2006-04-11 | Hoffman-La Roche, Inc. | Antibodies against human IL-12 |
| AU762756B2 (en) | 1998-05-18 | 2003-07-03 | Apoptosis Technology, Inc. | Compounds, screening methods, and uses involving anti-apoptotic genes and gene products |
| US6326354B1 (en) | 1998-08-19 | 2001-12-04 | Washington University | Modulation of apoptosis with bid |
| AU5233799A (en) | 1998-08-19 | 2000-03-14 | Washington University | Modulation of apoptosis with bid |
| WO2002005835A2 (en) | 2000-07-17 | 2002-01-24 | Washington University | Modulation of apoptosis |
| US20020177692A1 (en) | 2001-04-16 | 2002-11-28 | Myriad Genetics, Incorporated | BCL-XL-interacting protein and use thereof |
| US20030073661A1 (en) | 2001-09-24 | 2003-04-17 | Shigemi Matsuyama | Method of modulating or examining Ku70 levels in cells |
| AU2002364364A1 (en) | 2001-12-31 | 2003-07-24 | Dana-Farber Cancer Institute, Inc. | Method of treating apoptosis and compositions thereof |
| WO2004022580A2 (en) | 2002-09-09 | 2004-03-18 | Dana-Farber Cancer Institute, Inc. | Bh3 peptides and method of use thereof |
| RU2345137C2 (ru) | 2002-12-26 | 2009-01-27 | Закрытое акционерное общество "ЕВРОГЕН" | Флуоресцирующие белки из веслоногих ракообразных и способы их применения |
| CA2521077A1 (en) | 2003-04-01 | 2004-10-28 | Monogram Biosciences, Inc. | Erbb surface receptor complexes as biomarkers |
| FR2855650B1 (fr) | 2003-05-30 | 2006-03-03 | Soitec Silicon On Insulator | Substrats pour systemes contraints et procede de croissance cristalline sur un tel substrat |
| CN1302004C (zh) | 2003-08-22 | 2007-02-28 | 浙江海正药业股份有限公司 | 一种阿糖胞苷的制备方法 |
| EP1997828B1 (en) | 2003-11-05 | 2017-10-04 | Dana-Farber Cancer Institute, Inc. | Stabilized alpha helical peptides from BCL-2 and uses thereof |
| WO2005079434A2 (en) | 2004-02-17 | 2005-09-01 | The University Of North Carolina At Chapel Hill | Modulation of epidermal growth factor heterodimer activity |
| CA2563074C (en) | 2004-04-09 | 2014-05-20 | Genomic Health, Inc. | Gene expression markers for predicting response to chemotherapy |
| EP2008106A2 (en) | 2006-03-31 | 2008-12-31 | Dana-Farber Cancer Institute | Methods of determining cellular chemosensitivity |
| WO2008021484A2 (en) | 2006-08-16 | 2008-02-21 | Eutropics Pharmaceuticals | Assay system to identify therapeutic agents |
| EP2952522B1 (en) | 2007-01-31 | 2019-10-30 | Dana-Farber Cancer Institute, Inc. | Stabilized p53 peptides and uses thereof |
| US20090030005A1 (en) | 2007-07-19 | 2009-01-29 | Amgen Inc. | Combinations for the treatment of cancer |
| EP2649997B1 (en) | 2007-12-10 | 2019-01-23 | Sunesis Pharmaceuticals, Inc. | (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for use in the treatment of myelodyspastic syndrome |
| US8168755B2 (en) | 2008-05-07 | 2012-05-01 | Eutropics Pharmaceuticals, Inc. | Antibodies specific to heterodimers of Bcl-2 family and uses thereof |
| US20100015058A1 (en) | 2008-06-25 | 2010-01-21 | Stanford University | Radiolabeled bbn-rgd heterodimers for cancer targeting |
| US9492449B2 (en) * | 2008-11-13 | 2016-11-15 | Gilead Calistoga Llc | Therapies for hematologic malignancies |
| MX2011008488A (es) | 2009-02-11 | 2011-10-24 | Abbott Lab | Metodos y composiciones para identificar, clasificar y monitorear individuos que tienen tumores y canceres resistentes al inhibidor de la familia de bcl-2. |
| JP5718319B2 (ja) | 2009-05-14 | 2015-05-13 | ネステク ソシエテ アノニム | Ｈｅｒ２標的化療法に対する乳癌細胞の感受性を決定するためのバイオマーカー |
| WO2011088137A2 (en) | 2010-01-12 | 2011-07-21 | H. Lee Moffitt Cancer Center & Research Institute | Bad pathway gene signature |
| WO2012088438A1 (en) | 2010-12-22 | 2012-06-28 | Eutropics Pharmaceuticals, Inc. | Compositions and methods useful for treating diseases |
| US9051305B2 (en) | 2011-03-08 | 2015-06-09 | Eutropics Pharmaceuticals, Inc. | Compositions and methods useful for treating diseases |
| US9012215B2 (en) * | 2011-09-22 | 2015-04-21 | The Johns Hopkins University | Methods for identifying leukemia stem cells and distinguishing them from normal hematopietic stem cells in patients with acute myeloid leukemia: uses in diagnosis, treatment, and research |
| WO2013138702A2 (en) | 2012-03-15 | 2013-09-19 | Bristol-Myers Squibb Company | Methods for predicting gastrointestinal immune-related adverse events (gi-irae) in patients treated with modulation of the co-stimulatory pathway |
| KR102062416B1 (ko) | 2012-05-10 | 2020-01-03 | 유트로픽스 파마슈티컬스, 인크. | 실용 가능한 암 진단 대체 법 |
| HK1213046A1 (zh) | 2012-09-19 | 2016-06-24 | Dana-Farber Cancer Institute, Inc. | 動態bh3分析 |
| EP2922544B1 (en) * | 2012-11-21 | 2018-08-01 | Eutropics Pharmaceuticals, Inc. | Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives |
| CA2922503C (en) | 2013-09-19 | 2021-10-26 | Dana-Farber Cancer Institute, Inc. | Methods of bh3 profiling |
| WO2015066305A1 (en) * | 2013-10-30 | 2015-05-07 | Eutropics Pharmaceuticals, Inc. | Methods for determining chemosensitivity and chemotoxicity |
| AU2016253957C1 (en) | 2015-04-27 | 2021-04-01 | Dana-Farber Cancer Institute, Inc. | High throughput BH3 profiling: a rapid and scalable technology to BH3 profile on low numbers of cells |
-
2016
- 2016-01-12 US US15/542,520 patent/US10793915B2/en not_active Expired - Fee Related
- 2016-01-12 EP EP16737714.2A patent/EP3245301B1/en active Active
- 2016-01-12 JP JP2017536828A patent/JP6774951B2/ja not_active Expired - Fee Related
- 2016-01-12 CA CA2974240A patent/CA2974240A1/en active Pending
- 2016-01-12 AU AU2016206882A patent/AU2016206882B2/en not_active Ceased
- 2016-01-12 WO PCT/US2016/013003 patent/WO2016115105A1/en not_active Ceased
- 2016-01-12 CN CN201680011405.2A patent/CN107406881B/zh not_active Expired - Fee Related
- 2016-01-12 KR KR1020177022475A patent/KR20170126867A/ko not_active Ceased
- 2016-01-12 HK HK18106406.5A patent/HK1247250A1/zh unknown
-
2020
- 2020-06-25 US US16/912,097 patent/US20200392585A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018503092A5 (https=) | ||
| JP2015519565A5 (https=) | ||
| Blum et al. | Sarcomatoid renal cell carcinoma: biology, natural history and management | |
| KR102062416B1 (ko) | 실용 가능한 암 진단 대체 법 | |
| JP2019162153A (ja) | 示差的ｂｈ３ミトコンドリアプロファイリング | |
| US20180100859A1 (en) | Surrogate functional biomarker for solid tumor cancer | |
| ES2980135T3 (es) | Métodos para monitorizar la respuesta al tratamiento y la progresión de la enfermedad en sujetos usando células circulantes | |
| Tan et al. | Prognostic features of Annexin A2 expression in prostate cancer | |
| Pansare et al. | Increased expression of hypoxia-inducible factor 1α in type I and type II endometrial carcinomas | |
| Brisam et al. | Expression of MAGE-A1-A12 subgroups in the invasive tumor front and tumor center in oral squamous cell carcinoma | |
| Laurent et al. | Detection of minimally disseminated disease in the cerebrospinal fluid of children with high-risk retinoblastoma by reverse transcriptase-polymerase chain reaction for GD2 synthase mRNA | |
| US20080311039A1 (en) | Therapeutic and Prognostic Factor Yy1 in Human Cancer | |
| Yuan et al. | Expression of bile duct transcription factor HNF1β predicts early tumor recurrence and is a stage-independent prognostic factor in hepatocellular carcinoma | |
| Abike et al. | PCNA and Ki-67 in endometrial hyperplasias and evaluation of the potential of malignancy | |
| Lee et al. | Epigenetic role of histone 3 lysine methyltransferase and demethylase in regulating apoptosis predicting the recurrence of atypical meningioma | |
| Dudasova et al. | Artemis, a novel guardian of the genome | |
| Akino et al. | High apoptotic activity and low epithelial cell proliferation with underexpression of p21WAF1/CIP1 and p27Kip1 of mucinous carcinomas of the colorectum: comparison with well-differentiated type | |
| Török-Nagy et al. | Evaluation of the performance of a human D-dimer test in dogs with neoplasia | |
| CN102099493A (zh) | 用于预测对抗癌疗法的反应性的组合方法 | |
| Gröbe et al. | Outcome and fewer indications for adjuvant therapy for patients with oral squamous cell carcinomas under standardized tumor board conditions | |
| JP5295268B2 (ja) | がん疾患に罹患している患者の生物学的療法に対する感受性を測定するための方法 | |
| JP5574522B2 (ja) | 癌マーカー及び癌細胞の検査方法 | |
| Naz et al. | Expression of bcl-2 in primary and recurrent odontogenic keratocysts in comparison with other odontogenic lesions | |
| Du et al. | CEBPA enhances tumor radiosensitivity through ferroptosis and associates with tumor immune microenvironment | |
| WO2019077080A1 (en) | ASSESSING THE RISK OF METASTATIC RECHUTE IN PATIENTS WITH BREAST CANCER |